RARRES1 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P49788 |
---|---|
Clone Names | 100405063 |
Gene ID | 5918 |
---|---|
Other Names | Retinoic acid receptor responder protein 1, Phorbol ester-induced gene 1 protein, PERG-1, RAR-responsive protein TIG1, Tazarotene-induced gene 1 protein, RARRES1, PEIG1, TIG1 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP13138b was selected from the C-term region of RARRES1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | RARRES1 |
---|---|
Synonyms | PEIG1, TIG1 |
Function | Inhibitor of the cytoplasmic carboxypeptidase AGBL2, may regulate the alpha-tubulin tyrosination cycle. |
Cellular Location | Membrane; Single- pass type III membrane protein. Secreted |
Tissue Location | Detected in urine (at protein level). |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene was identified as a retinoid acid (RA)receptor-responsive gene. It encodes a type 1 membrane protein. Theexpression of this gene is upregulated by tazarotene as well as byretinoic acid receptors. The expression of this gene is found to bedownregulated in prostate cancer, which is caused by themethylation of its promoter and CpG island. Alternatively splicedtranscript variant encoding distinct isoforms have been observed.
References
Wheeler, H.E., et al. PLoS Genet. 5 (10), E1000685 (2009) :Kwok, W.K., et al. Cancer Genet. Cytogenet. 194(1):58-64(2009)Ohnishi, S., et al. Cell Prolif. 42(3):309-316(2009)Son, M.S., et al. Oncol. Res. 17 (11-12), 571-580 (2009) :Shutoh, M., et al. Cancer 104(8):1609-1619(2005)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.